Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent and/or unresectable meningioma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UNICANCER
• Treatments: Hydroxyurea

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven progressive meningioma that is not curable by surgery

PATIENT CHARACTERISTICS:

Age:

• 16 and over

Performance status:

• Karnofsky 70-100%

Life expectancy:

• Over 3 months

Hematopoietic:

• WBC at least 3,000/mm^3

• Platelet count at least 100,000/mm^3

Hepatic:

• Bilirubin no greater than 2 times upper limit of normal (ULN)

• AST and ALT no greater than 2 times ULN

• Alkaline phosphatase no greater than 2 times ULN

Renal:

• Creatinine no greater than 2 times ULN

Other:

• Not pregnant or nursing

• Fertile patients must use effective contraception during and for 6 months after study

• No other malignancy

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy

• No other concurrent chemotherapy

Endocrine therapy:

• Concurrent corticosteroids allowed for control of intracranial pressure

Radiotherapy:

• Prior radiotherapy allowed

• No concurrent radiotherapy

Surgery:

• See Disease Characteristics

Other:

• At least 1 year since prior experimental therapy